Discussion
Treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2i), a medication used for type 2 diabetes, may reduce the risk of death and heart attacks in people with Fabry disease, according to a new analysis. “In this real-world cohort of patients with [Fabry disease], exposure to [SGLT2i] was associated with a lower…